TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Provision of signed and dated informed consent form(ICF)~* ≥18 years old~* Subject diagnosed of AML MRD.~* Eastern Cooperative Oncology Group (ECOG) performance status ≤1~* Adequate organ function as defined in the protocol~* Donor specific antibody (DSA) to QN-030a: MFI ≤ 2000~Key Exclusion Criteria:~* Allergic to drug used in this study~* Accept other anti-tumor drug within 2 weeks of day 0 (first QN-030a dose infusion)~* Prior allogeneic hematopoietic stem cell transplant (HSCT) within 6 months of Day 0, received systemic immunosuppressive therapy within 7 days of Day 0, or likely to require systemic immunosuppressive therapy~* Acute Promyelocytic Leukemia (APL)~* Active central nervous system Leukemia.~* Uncontrolled, active clinically significant infection~* Clinically significant cardiovascular disease as defined in the protocol~* History of central nervous system (CNS) disease such as stroke, epilepsy.~* Females are pregnant or lactating~* Known HIV infection, active Hepatitis B (HBV) or Hepatitis C (HCV) infection~* Investigator-assessed presence of any medical or social issues that are likely to interfere with study conduct or may cause increased risk to subject

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QN-030a (Type: EXPERIMENTAL): QN-030a in Adult subjects with MRD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Signature Acetabular Posterior/Lateral Data Collection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with one of the following indication:~* Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis.~* Rheumatoid arthritis.~* Correction of functional deformity.~* Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques.~Additional inclusion criteria include:~* Subjects requiring primary total hip arthroplasty~* 20 to 75 years of age~* Subjects with a diagnosis of osteoarthritis or traumatic arthritis~* Subjects willing to return for follow-up evaluations.~* Subjects who can read, understand study information and give written consent without representation of a legally authorized representative.~* Bilateral patients are included if staged.~* Only Posterior Lateral Approach can be used for inclusion in this study~Exclusion Criteria:~- Exclusion criteria should be in accordance with Contraindications for the Biomet primary acetabular cup.~Absolute contraindications include: infection, sepsis, osteomyelitis, and failure of a previous joint replacement.~Additional contraindications include:~* Subjects whose bony structure deviates substantially from the general norm sufficiently to require non-standard implants. Specific examples of these are total dislocation of the hip, severe coxa vera deformity, and severe forms of multiple epiphyseal dysplasia~* Subjects unable to cooperate with and complete the study~* Dementia and inability to understand and follow instructions~* Neurological conditions affecting movement~* Pregnancy~Additional exclusion criteria include:~* Surgical approach other than posterior lateral.~* Simultaneous bilateral procedures

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Signature Cutting Guides (Type: ACTIVE_COMPARATOR): Patients indicated for a Posterior Lateral THA utilizing non implantable Signature Cutting Guides during surgery.
- Conventional Instrumentation (Type: ACTIVE_COMPARATOR): Patients indicated for a Posterior Lateral THA utilizing non implantable Conventional Instrumentation during surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, ≥ 18 and \< 80 years of age.~* CD20-positive diffuse large B-cell lymphoma.~* Low-intermediate, high-intermediate, or high risk disease and/or bulky tumor (largest diameter ≥ 7.5 cm).~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.~Exclusion Criteria:~* Prior treatment for diffuse large B-cell lymphoma.~* Types of non-Hodgkin's lymphoma other than diffuse large B-cell lymphoma (DLBCL).~* Central nervous system (CNS) involvement of lymphoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + rituximab + CHOP (Type: EXPERIMENTAL): Patients received bevacizumab 5 mg/kg/week on Day 1 of each cycle + rituximab 375 mg/m\^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone).
- Placebo + rituximab + CHOP (Type: ACTIVE_COMPARATOR): Patients received placebo to bevacizumab on Day 1 of each cycle + rituximab 375 mg/m\^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Tracking Goals in Counselling

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All clients referred for counselling in the service.~Exclusion Criteria:~* Service users who do not understand verbal and written communication in English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Completing the Goals Form (Type: EXPERIMENTAL): In this arm, client participants will complete the Goals Form in collaboration with their therapists at the start of every session.
- therapy as usual (Type: NO_INTERVENTION): In this arm, clients will have therapy as usual.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Project 1: ACHIEVE- HTN

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* In order to be eligible to participate in this study, an individual must meet all of the following criteria:~  1. Self-identified Black/African Americans~ 2. Detroit-area residents (defined as those who attend attended a Detroit-area community event)~ 3. \> 18 years of age~ 4. Screening systolic BP 130-139 and diastolic BP \< 90 mm Hg~ 5. Not currently taking medications for HTN (Untreated)~ 6. 10-year cardiovascular risk \< 10% per ASCVD calculator (as such nearly all patients will be \<50-55 years of age)~ 7. Baseline home systolic BP 120-159 mm Hg and diastolic BP \< 100 mm Hg~Exclusion Criteria:~* An individual who meets any of the following criteria will be excluded from participation in this study:~  1. History of clinical cardiovascular disease (CVD)~ 2. History of kidney disease or eGFR \<60 mL/min from screening labs~ 3. Self-reported pregnancy (or planning to be pregnant in the next year)~ 4. History of diabetes or HbA1c \> 6.5% from SOC screening labs~ 5. Non-HDL-C \> 220 mg/dL from SOC labs (potential genetic hyperlipidemia)~ 6. Arm circumference \> 18'' (home BP arm cuff will be inaccurate)~ 7. Baseline home BP average \> 160mm Hg systolic and/or \>100 mm Hg diastolic

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: t

Study Arms:
- PAL2 Intervention (Type: EXPERIMENTAL): Overall study cohort will be enrolled into non-randomized active treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Continuing Evaluation of the LungPoint ATV System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Surgical candidates age 21-75 years at screening~2. Highly suspicious SPN, defined as distinct nodule with a diameter of 10-30 mm in its largest dimension~3. No known endobronchial tumor~4. Tumor located anywhere in parenchymal tissue \>1 cm from pleura and accessible bronchoscopically through a POE.~5. Willing to participate in all aspects of study protocol for duration of study~6. Able to understand study requirements~7. Signs study-related informed consent document~Exclusion Criteria:~1. Any contraindication to bronchoscopy, for example: (a.) Untreatable life-threatening arrhythmias, (b.) Inability to adequately oxygenate the patient during the procedure, (c.) Acute respiratory failure with hypercapnia (unless the patient is intubated and ventilated), (d.) Recent myocardial infarction, (e.) Previously diagnosed high-grade tracheal obstruction, (f.) Uncorrectable coagulopathy.~2. Known coagulopathy~3. Platelet dysfunction or platelet count \< 100 x 103 cells/mm3~4. History of major bleeding with bronchoscopy~5. Pulmonary hypertension with mean PAP \>25 mm~6. Moderate-to-severe pulmonary fibrosis~7. Moderate to severe emphysema or COPD with FEV1 \<60% predicted or RV \>200% predicted~8. Bullae \>5 cm located in vicinity of target SPN or ATV tunnel~9. Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy or ATV tunneling, for example: (a.) ASA class \> 3, (b.) \> stage 3 heart failure, (c.) severe cachexia, (d.) severe respiratory insufficiency or hypoxia~10. Ongoing systemic infection~11. Contraindication to general anesthesia~12. Chronic use of anticoagulants (e.g., heparin, Warfarin) or antiplatelet agents (e.g. aspirin, clopidogrel)~13. Participation in any other study in last 30 days~14. Prior thoracic surgery on the same side of the lung as the SPN~15. Breastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study.~16. Life expectancy of less than one year.~17. Patients with known intrapulmonary metastases of extrapulmonary cancer/tumors~18. Scheduled for lung surgery within 7 days post-scheduled diagnostic bronchoscopy

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Navigation and tissue sampling (Type: EXPERIMENTAL): Guided bronchoscopic navigation and lung tissue sampling using the LungPoint ATV System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Fetal and Maternal Microbiota in Preganant Women With Fetal Defect Growth

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Intrauterine Growth restriction (32-36 weeks)~* Vaginal delivery~* Delivery at 37 weeks~Exclusion Criteria:~* Alcohol, tabacco or other drugs consumption during pregnancy~* Antibiotic use before recruitment (3 months) or during pregnancy until delivery~* Gestational diabetes~* Fetuses anormalities

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Fetal growth restriction (Type: None): 63 fetuses with defects in fetal growth qith an estimated fetal weight below 10th percentile
- Control group (Type: None): 63 control fetuses with an estimated fetal weight about the 10th percentile

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Measuring Sedation in the Intensive Care Unit Using Wireless Accelerometers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Admitted to the neuro ICU at University of Minnesota~Exclusion Criteria:~* Unable to wear accelerometer device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Medical device, accelerometer (Type: None): A wrist and chest accelerometer will be worn for the duration of stay in the ICU. Data will be generated from patient movement and recorded. Neither the generated data or the worn devices will influence care team's decisions during the patients' stay.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Women ≥ 18 years, Negative pregnancy test at screening and life expectancy of at least 3 months~* metastatic (stage IV) and not curable adenocarcinoma of the breast~* Measurable disease, defined as at least one lesion that is measurable in one dimension (RECIST)~* HER-2 overexpression 3+ or 2+ FISH positive~* Patients must have received one prior therapy with trastuzumab as last treatment before entry into the study. If trastuzumab was given as single agent treatment, patients must have received prior chemotherapy for metastatic disease~* Trastuzumab has been discontinued before study entry~* disease had progressed during or after trastuzumab therapy~* Eastern Cooperative Oncology Group (ECOG)performance score of ≤ 2~* Adequate hematological, liver and kidney function~Key Exclusion Criteria:~* Women who are pregnant or breast feeding~* Any history or symptoms indicative of brain or central nervous system metastases~* Prior diagnosis of any malignancy not cured by surgery alone less than 5 years before study entry (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin)~* Human anti-murine antibody positive or hypersensitivity to murine proteins and any other component of the study drug~* Known autoimmune diseases, Human immunodeficiency virus (HIV), hepatitis B or C infection as well as other acute or chronic infection or other concurrent non-malignant co-morbidities that are uncontrolled~* Any concurrent chemotherapy, hormonal therapy, immunotherapy or corticoid therapy~* Concurrent antibiotic treatment~* Any concurrent investigational treatment for metastatic disease~Cardiovascular exclusion criteria:~* Unstable or uncontrolled pectorial angina~* Myocardial infarction during the last 6 months~* Valvular heart disease that requires treatment~* Cardiomyopathy (congestive, hypertrophic or restrictive)~* Acute myocarditis~* Congestive heart failure (CHF): dyspnea, clinically or radiologically diagnosed~* Left ventricular ejection fraction (LVEF)outside institution's normal range based on echocardiography at rest~* Left ventricular diameter \> 56 mm based on M-mode echocardiography at rest~* Arrhythmias that require treatment (atrioventricular block II/III degree, atrial fibrillation, ventricular tachycardia)~* Poorly or uncontrolled hypertension, asthma, seizures, allergies, pulmonary dysfunction

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 and Type 2 Diabetes mellitus~* MRSA infected foot ulcus Wagner 1-2 without primary surgical intervention~* Therapy duration will last at least more than 5 days~* men and women age 18 - 80 years~* Declaration of patient's consent~* Ability and willingness to give written informed consent and to comply with the requirements of the study~* Sexually active females, unless surgically sterile, must be willing to use 2 forms of contraception through the end of the study. Sexually active woman must, except if they were surgically sterilized, have to use for already 30 days before first dose of study medication an effective method of pregnancy prevention. Acceptable forms of contraception for female subjects include: oral, transdermal, injectable or implanted contraceptives, intrauterine device (IUD), female condom, diaphragm with spermicide, cervical cap, absolute waiver of sexual intercourse, use of a condom by the sexual partner, or sterile sexual partner. Male subjects with partners of child-bearing potential should use barrier contraception in addition to having their partners use another method of contraception.~Exclusion Criteria:~* Osteomyelitis according to international consensus guideline (3 of 5 criteria apply for diagnosis)~* Presence of a severe nephropathy (creatinine clearance \< 30 ml/min)~* Advanced diabetic retinopathy~* Simultaneous participation in another study or participation in a study in the past 30 days~* Non permissible concomitant medication e.g. therapy regimen using several antibiotics~* Contraindication for antibiotics~* Dialysis essential~* Pregnancy (to be determined by pregnancy test) or unsafe contraception~* Neutropenia~* immunosuppression (oral immunosuppressives, Corticoids exaggerating 7.5 mg Prednisolon-equivalents)~* Chronic liver disease (AST or ALT increased to 10fold, bilirubin increased to threefold compared to normal values)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Daptomycin (Type: EXPERIMENTAL): Infusion of Daptomycin (6 mg/kg bodyweight) once daily
- Vancomycin (Type: ACTIVE_COMPARATOR): Vancomycin once daily (effective blood-plasma concentration of 15 mg/l)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of CLL or SLL based on IWCLL Criteria~* Measurable or evaluable disease based on IWCLL criteria~* Previously untreated patients who have been counseled on approved alternative therapeutic options. Not a candidate for fludarabine/cyclophosphamide/rituximab (FCR) or has preference to not receive chemotherapy.~* Eastern Cooperative Oncology Group (ECOG) status of 0-2.~* Adequate bone marrow, renal, liver, cardiac and pulmonary function.~* Life expectancy of greater than or equal to 6 months.~Exclusion Criteria:~* Receipt of other cancer therapy, immunomodulatory drug therapy or immunosuppressive therapy within 4 weeks prior to 1st dose.~* Receipt of corticosteroids \> 20 mg/day within 4 weeks prior to1st dose~* Major surgery or radiation within 4 weeks prior to 1st dose~* Presence of uncontrolled infection requiring systemic therapy~* Active second malignancy other than non-melanoma skin cancer~* Uncontrolled autoimmune anemia or thrombocytopenia~* Receipt of any investigational agent within 4 weeks prior to 1st dose~* Pregnant or lactating female~* Any severe, acute or chronic medical or psychiatric condition, or lab abnormality that may increase the risk associated with trial participation, study drug administration or interfere with informed consent process or compliance with requirements of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A6 (Type: EXPERIMENTAL): A6 is administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues